Last reviewed · How we verify
chiglitazar sodium tablets — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
chiglitazar sodium tablets (chiglitazar sodium tablets) — Chipscreen Biosciences, Ltd.. Chiglitazar acts as a pan-PPAR agonist, activating all three PPAR subtypes (alpha, gamma, and delta) to regulate glucose and lipid metabolism.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| chiglitazar sodium tablets TARGET | chiglitazar sodium tablets | Chipscreen Biosciences, Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- chiglitazar sodium tablets CI watch — RSS
- chiglitazar sodium tablets CI watch — Atom
- chiglitazar sodium tablets CI watch — JSON
- chiglitazar sodium tablets alone — RSS
Cite this brief
Drug Landscape (2026). chiglitazar sodium tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/chiglitazar-sodium-tablets. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing